Patents by Inventor Jim Tartaglia

Jim Tartaglia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multi-antigen vectors of melanoma
    Publication number: 20060127360
    Abstract: The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.
    Type: Application
    Filed: September 3, 2004
    Publication date: June 15, 2006
    Inventors: Neil Berinstein, Jim Tartaglia, Mark Parrington, Dennis Panicali, Linda Gritz
  • Cort-PCR Assay for the discrimination of endogenous reverse transcriptase activity in eukaryotic cell lines from infectious retrovirus contamination
    Publication number: 20030008280
    Abstract: The present invention relates to the detection of the presence of reverse transcriptase enzymatic activity in eukaryotic cell lines. Specifically, the present invention comprises a method for discriminating between endogenous reverse transcriptase activity in a substrate cell line (e.g., avian) used as substrates for the manufacture of biological products (including viral vaccines) from exogenous infectious retrovirus by using a combination of transmissibility assay (viral replication) and PBRT assay (RT-PCR). Appropriate levels of viral amplification and number of PCR cycles are determined and employed that permit detection of exogenous infectious RT activity but not endogenous RT activity.
    Type: Application
    Filed: August 9, 2002
    Publication date: January 9, 2003
    Inventors: Scott Goebel, Maurice Harmon, Jim Tartaglia, William Lapps, Francois Pelloquin, Dennis W. Trent
  • CoRT-PCR assay for the discrimination of endogenous reverse transcriptase activity in eukaryotic cell lines from infectious retrovirus contamination
    Patent number: 6465171
    Abstract: The present invention relates to the detection of the presence of reverse transcriptase enzymatic activity in eukaryotic cell lines. Specifically, the present invention comprises a method for discriminating between endogenous reverse transcriptase activity in a substrate cell line (e.g., avian) used as substrates for the manufacture of biological products (including viral vaccines) from exogenous infectious retrovirus by using a combination of transmissibility assay (viral replication) and PBRT assay (RT-PCR). Appropriate levels of viral amplification and number of PCR cycles are determined and employed that permit detection of exogenous infectious RT activity but not endogenous RT activity.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: October 15, 2002
    Assignee: Aventis Pasteur
    Inventors: Scott Goebel, Maurice Harmon, Jim Tartaglia, William Lapps, Francois Pelloquin, Dennis W. Trent